Literature DB >> 14713822

Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity.

Andre Reitz1, Brigitte Schurch.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 14713822     DOI: 10.1097/01.ju.0000108407.53880.6a

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  9 in total

Review 1.  [Botulinum toxin in urology. Indications and results].

Authors:  B Schurch; A Reitz
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

Review 2.  Botulinum toxin treatment for overactive bladder: risk of urinary retention.

Authors:  Ahmed M Shaban; Marcus J Drake
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

3.  Botulinum Toxin Use in Neurourology.

Authors:  Benoit Peyronnet; Xavier Gamé; Gregory Vurture; Victor W Nitti; Benjamin M Brucker
Journal:  Rev Urol       Date:  2018

4.  Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art.

Authors:  Victor W Nitti
Journal:  Rev Urol       Date:  2006

Review 5.  Botulinum toxin for the management of bladder dysfunction.

Authors:  Brigitte Schurch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 6.  [Botulinum toxin for the treatment of overactive bladder--an overview].

Authors:  C Seif; S Boy; B Wefer; R Dmochowski; P M Braun; K-P Jünemann
Journal:  Urologe A       Date:  2008-01       Impact factor: 0.639

Review 7.  Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term solution?

Authors:  Darius J Unwala; Paholo Barboglio; Angelo E Gousse
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

Review 8.  The use of botulinum neurotoxin type A (BoNTA) in urology.

Authors:  A Apostolidis; C J Fowler
Journal:  J Neural Transm (Vienna)       Date:  2008-03-06       Impact factor: 3.575

Review 9.  A case for botulinum toxin-A in idiopathic bladder overactivity.

Authors:  Christopher P Smith; George T Somogyi; Michael B Chancellor; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.